Onyx Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for cancer. The company is focused on developing medicines that target key molecular pathways. The Company is a subsidiary of Amgen. Its Nexavar (sorafenib) Tablets are indicated for Advanced Kidney Cancer, Liver Cancer and for locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer. The Company’s Kyprolis (carfilzomib) for Injection is a proteasome inhibitor, for the treatment of patients with multiple myeloma. Its Carfilzomib and Oprozomib are indicated for multiple myeloma, Sorafenib is indicated for liver, thyroid and kidney cancer and Palbociclib is indicated for advanced breast cancer.